[go: up one dir, main page]

CL2011000064A1 - Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas. - Google Patents

Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas.

Info

Publication number
CL2011000064A1
CL2011000064A1 CL2011000064A CL2011000064A CL2011000064A1 CL 2011000064 A1 CL2011000064 A1 CL 2011000064A1 CL 2011000064 A CL2011000064 A CL 2011000064A CL 2011000064 A CL2011000064 A CL 2011000064A CL 2011000064 A1 CL2011000064 A1 CL 2011000064A1
Authority
CL
Chile
Prior art keywords
polymer
microparticles
pressure
liquefy
penetrate
Prior art date
Application number
CL2011000064A
Other languages
English (en)
Inventor
Andrew Naylor
Andrew Lester Lewis
Lisbeth Illum
Original Assignee
Critical Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Critical Pharmaceuticals Ltd filed Critical Critical Pharmaceuticals Ltd
Publication of CL2011000064A1 publication Critical patent/CL2011000064A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Proceso para preparar micropartículas que comprende contactar un material biológicamente activo, un polímero y un auxiliar de procesamiento con un fluido supercrítico, permitir que dicho fluido penetre y licue dicho polímero, y precipitar las micropartículas; uso de dicho auxiliar; micropartícula; y composición.
CL2011000064A 2008-07-11 2011-01-11 Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas. CL2011000064A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0812742.5A GB0812742D0 (en) 2008-07-11 2008-07-11 Process

Publications (1)

Publication Number Publication Date
CL2011000064A1 true CL2011000064A1 (es) 2011-06-24

Family

ID=39722153

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000064A CL2011000064A1 (es) 2008-07-11 2011-01-11 Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas.

Country Status (15)

Country Link
US (2) US9226900B2 (es)
EP (2) EP2320872B1 (es)
JP (1) JP5687191B2 (es)
KR (1) KR20110031378A (es)
CN (1) CN102149409B (es)
AU (1) AU2009269806A1 (es)
BR (1) BRPI0915856A2 (es)
CA (1) CA2730321C (es)
CL (1) CL2011000064A1 (es)
EA (1) EA018910B1 (es)
ES (1) ES2569383T3 (es)
GB (2) GB0812742D0 (es)
MX (1) MX2011000238A (es)
WO (1) WO2010004287A2 (es)
ZA (1) ZA201100970B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US20140112979A1 (en) 2011-07-04 2014-04-24 Statens Serum Institut Methods for producing liposomes
BR112014028951A8 (pt) * 2012-05-21 2021-09-14 Univ Colorado Regents Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
US20140154308A1 (en) * 2012-06-28 2014-06-05 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture
ITTO20130284A1 (it) * 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
CA2926358A1 (en) * 2013-10-08 2015-04-16 Ferring B.V. Microparticles comprising gnrh made by pgss
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
CN104764636A (zh) * 2014-12-04 2015-07-08 青岛科技大学 一种基于气体饱和溶液法制备pm2.5气溶胶的方法
EP3320019B1 (en) * 2015-07-09 2020-08-12 Evonik Operations GmbH Process for preparing poly(glycolide-co-lactide) copolymer microparticles
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101942449B1 (ko) 2016-12-13 2019-01-28 주식회사 삼양바이오팜 생분해성 고분자의 다공성 미립자, 및 이를 포함하는 고분자 필러
US12220486B2 (en) 2018-03-02 2025-02-11 Saint Joseph's University Polymer compositions for storage and release of polypeptides
CN114831930B (zh) * 2022-03-28 2023-09-05 厦门大学 一种胶原蛋白组装眼药、制备方法及应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4582731A (en) * 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4734451A (en) * 1983-09-01 1988-03-29 Battelle Memorial Institute Supercritical fluid molecular spray thin films and fine powders
US4734227A (en) * 1983-09-01 1988-03-29 Battelle Memorial Institute Method of making supercritical fluid molecular spray films, powder and fibers
US4598006A (en) * 1985-05-02 1986-07-01 Hercules Incorporated Method for impregnating a thermoplastic polymer
US4820752A (en) * 1985-10-21 1989-04-11 Berens Alan R Process for incorporating an additive into a polymer and product produced thereby
CN86103433A (zh) * 1986-05-21 1987-12-02 联合采煤公司 潮湿微粒中抽取水分的方法和设备
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
CN1008691B (zh) * 1986-06-28 1990-07-11 南通醋酸化工厂 灰黄霉素微粒结晶方法及其装置
US4775490A (en) 1987-07-30 1988-10-04 The Lubrizol Corporation Magnesium overbasing process
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
CA2017332A1 (en) 1989-06-29 1990-12-29 Richard W. Greiner Pharmaceutically impregnated catheters
GB8928250D0 (en) 1989-12-14 1990-02-21 Erba Carlo Spa Use of supercritical fluids to obtain porous sponges of biodegradable polymers
US5290827A (en) * 1991-03-27 1994-03-01 University Of Delaware Precipitation of homogeneous polymer mixtures from supercritical fluid solutions
US5158986A (en) * 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
EP0669858A4 (en) * 1992-11-02 1997-07-16 Ferro Corp METHOD FOR PRODUCING COATED MATERIALS.
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US5312882A (en) * 1993-07-30 1994-05-17 The University Of North Carolina At Chapel Hill Heterogeneous polymerization in carbon dioxide
US5866053A (en) * 1993-11-04 1999-02-02 Massachusetts Institute Of Technology Method for providing continuous processing of microcellular and supermicrocellular foamed materials
SI9400079B (sl) * 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
US5417992A (en) 1994-03-14 1995-05-23 Cornell Research Foundation, Inc. Supercritical fluid extrusion process and apparatus
EP0706821A1 (en) * 1994-10-06 1996-04-17 Centre De Microencapsulation Method of coating particles
US5500457A (en) * 1994-11-18 1996-03-19 Minnesota Mining And Manufacturing Company Water based toner receptive core/shell latex compositions
AU5717296A (en) * 1995-05-10 1996-11-29 Ferro Corporation Control system for processes using supercritical fluids
AU705968B2 (en) 1995-06-07 1999-06-03 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
EP0831787B1 (en) 1995-06-07 2001-08-22 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
CA2234232A1 (en) * 1995-10-26 1997-05-01 Mohammed Iqbal Composition for an ink-jet recording sheet
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
JP3703582B2 (ja) * 1996-02-22 2005-10-05 呉羽化学工業株式会社 電極バインダー、電極バインダー溶液、電極合剤、電極構造体および電池
US5766367A (en) * 1996-05-14 1998-06-16 Sandia Corporation Method for preventing micromechanical structures from adhering to another object
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
FR2753639B1 (fr) * 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
US5766637A (en) * 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
DE69841422D1 (de) 1997-10-15 2010-02-11 Univ South Florida Beschichtung von partikelmaterial mittels superkritischer flüssigkeit
IT1296464B1 (it) 1997-11-19 1999-06-25 Vectorpharma Int Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
JP3444781B2 (ja) 1998-03-10 2003-09-08 旭化成アイミー株式会社 医療用ポリマーの改質方法及び医療用ポリマー基材
US6864301B2 (en) * 1998-11-30 2005-03-08 The Regents Of The University Of Colorado Preparation and use of photopolymerized microparticles
US6403672B1 (en) * 1998-11-30 2002-06-11 University Technology Corporation Preparation and use of photopolymerized microparticles
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
KR20010002589A (ko) 1999-06-16 2001-01-15 김윤 생리활성물질 함유 생분해성 고분자 마이크로스피어의 제조방법
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
IT1318404B1 (it) 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
FR2809309B1 (fr) 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
US6579532B1 (en) * 2000-09-08 2003-06-17 Ferro Corporation Orthopedic mixtures prepared by supercritical fluid processing techniques
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
DE10054114A1 (de) * 2000-10-31 2002-05-16 Dupont Performance Coatings Verfahren zur Herstellung von Pulverlackzusammensetzungen
GB0030182D0 (en) 2000-12-11 2001-01-24 Univ Brunel Material processing
US20020130430A1 (en) * 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002090085A1 (en) 2001-05-04 2002-11-14 Trexel Inc Injection molding systems and methods
BR0210000A (pt) * 2001-05-30 2004-05-04 Csir Método de encapsular uma substância ativa
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
TW520383B (en) * 2001-08-03 2003-02-11 Ind Tech Res Inst Method of making porous biodegradable polymers
US6812548B2 (en) * 2001-11-30 2004-11-02 Intel Corporation Backside metallization on sides of microelectronic dice for effective thermal contact with heat dissipation devices
CA2478519C (en) 2002-03-07 2011-08-02 Eurand Pharmaceuticals Limited Process for loading and thermodynamically activating drugs on polymers by means of supercritical fluids
GB0205868D0 (en) 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
AU2003221888B2 (en) * 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
GB0221150D0 (en) 2002-09-12 2002-10-23 Matthews Siobhan O Incorporation of functional materials into bulk materials
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US20040154985A1 (en) * 2003-02-07 2004-08-12 Ferro Corporation Method and apparatus for producing particles via supercritical fluid processing
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US8142814B2 (en) * 2003-02-07 2012-03-27 Ferro Corporation Method and apparatus for supercritical fluid assisted particle production
WO2005005010A2 (en) * 2003-02-21 2005-01-20 Ferro Corporation Methods and apparatus for producing composite particles using supercritical fluid as plasticizing and extracting agent
EP1596969B1 (en) * 2003-02-24 2015-07-22 Ferro Corporation Method for enhanced size reduction of particles
US7455797B2 (en) * 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
FR2854071B1 (fr) * 2003-04-25 2009-01-30 Ethypharm Sa Procede de dispersion de substances hydrosolubles ou hydrophiles dans un fluide a pression supercritique
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
US7767118B2 (en) * 2003-06-03 2010-08-03 Ferro Corporation Nanoparticles from supercritical fluid antisolvent process using particle growth and agglomeration retardants
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP2007531701A (ja) 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
WO2005022603A2 (en) * 2003-09-02 2005-03-10 Integral Technologies, Inc. Low cost conductive containers manufactured from conductive loaded resin-based materials
JP2007509220A (ja) 2003-10-23 2007-04-12 ユニバーシテイ・オブ・ノツテインガム 活性ポリマー押出物の調製
US7208106B2 (en) 2003-10-24 2007-04-24 Ferro Corporation Method of forming particles
US20070102836A1 (en) 2004-01-28 2007-05-10 Japan Science And Technology Agency Method for producing fine particles using method of rapid expansion into poor solvent from supercritical fluid
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2006016981A2 (en) * 2004-07-12 2006-02-16 Ferro Corporation Production of porous materials by supercritical fluid processing
KR100622996B1 (ko) 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
GB0602637D0 (en) 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
EP2079767B1 (en) 2006-10-11 2014-08-27 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
GB0812740D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Composition
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process

Also Published As

Publication number Publication date
ES2569383T3 (es) 2016-05-10
MX2011000238A (es) 2011-05-10
WO2010004287A3 (en) 2010-05-20
EP3011955A1 (en) 2016-04-27
CN102149409B (zh) 2014-12-31
EA018910B1 (ru) 2013-11-29
JP2011527328A (ja) 2011-10-27
EA201170179A1 (ru) 2011-06-30
US9226900B2 (en) 2016-01-05
EP2320872B1 (en) 2016-02-10
KR20110031378A (ko) 2011-03-25
GB0812742D0 (en) 2008-08-20
GB2474002A (en) 2011-03-30
CA2730321C (en) 2017-05-23
WO2010004287A2 (en) 2010-01-14
ZA201100970B (en) 2012-07-25
US20160074327A1 (en) 2016-03-17
BRPI0915856A2 (pt) 2015-11-03
EP2320872A2 (en) 2011-05-18
US20110172141A1 (en) 2011-07-14
CA2730321A1 (en) 2010-01-14
JP5687191B2 (ja) 2015-03-18
AU2009269806A1 (en) 2010-01-14
GB201102017D0 (en) 2011-03-23
CN102149409A (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
CL2011000064A1 (es) Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas.
CL2008001753A1 (es) Proceso para preparar biomasa solida para procesamiento de una mezcla acuosa que comprende triturar la biomasa, agregar un agente de dispersion y contactarla con un catalizador.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EP4545544A3 (en) Modified crispr rna and modified single crispr rna and uses thereof
MX2016008086A (es) Mezclas que comprenden un polímero superabsorbente (sap) y un bioplaguicida.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
BRPI0810874A2 (pt) Líquido iônico, proceso para preparar um líquido iônico, e, uso de líquidos iônicos.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2012001019A1 (es) Composicion farmaceutica que comprende una proenzima de proteasa seleccionada de al menos tripsinogeno y quimiotripsinogeno y un agente activo seleccionado de al menos un compuesto de selenio, un compuesto vanilloide, un agente reductor de glicolisis citoplasmica y opcionalmente una glucosidohidrolasa; y uso para tratar cancer.
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
NZ728484A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
BR112015013859A2 (pt) corpo de carbono ferromagnético, processos para a produção de um corpo de carbono ferromagnético e de um corpo de carbono, uso de um corpo de carbono ferromagnético, e, catalisador
NZ731103A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
ECSP17059101A (es) Composición ácida a base de leonardita y aminoácidos
BR112013020841B8 (pt) Processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos
NZ726907A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
MX2016006306A (es) Agente de retencion de fluidez para composiciones hidraulicas, compatible con un agente reductor de agua tipo polimero en peine.
BR112015007737A2 (pt) complexo oxo-nitrogenado de cobalto, sistema catalítico compreendendo o dito complexo oxo-nitrogenado e processo para a (co)polimerização de dienos conjugados
BR112013010491A2 (pt) pó de poliol e polissacarídeo comprimível e altamente viscoso
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
CL2008000675A1 (es) Compuestos derivados de heterociclos sulfonilados; metodo para preparar dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer de mama, entre otras enfermedades.